Preferences help
enabled [disable] Abstract
Number of results
2016 | 6 | 1 | A5-7
Article title

Myeloma and amyloid

Title variants
Languages of publication
Physical description
  • University of Minnesota, Division of Hematology , Oncology and Transplantation, United States
  • Maine Medical Centre, Division of Cardiology , United States
  • Vanderbilt University, Division of Cardiology, United States Correspondence
  • 1. Kumar SK, Dispenzieri A, Lacy MQ et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122-1128.
  • 2. Attal M, Lauwers-Cances V, Hulin C et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 Trial). Blood 2015; 126(23).
  • 3. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352(24): 2487-2498.
  • 4. San Miguel JF, Schlag R, Khuageva NK et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359(9): 906-917.
  • 5. Stewart AK, Rajkumar SV, Dimopoulos MA et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372(2): 142-152.
  • 6. Shah JJ, Stadtmauer EA, Abonour R et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015; 126(20): 2284-2290.
  • 7. Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res 2015; 21(21): 4767- -4773.
  • 8. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction – Alzheimer’s disease of the heart? N Engl J Med 2013; 368(5): 455-464.
  • 9. Herrmann J, Wohlert C, Saguner AM et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 2013; 15(6): 614-623.
  • 10. Ranek MJ, Zheng H, Huang W et al. Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload. J Mol Cell Cardiol 2015; 85: 273-281.
  • 11. Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS One 2014; 9(1): e87671.
  • 12. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98(11): 1753-1761.
  • 13. Atrash S, Tullos A, Panozzo S et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 2015; 5: e272.
  • 14. Danhof S, Schreder M, Rasche L et al. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. Eur J Haematol 2015 [doi: 10.1111/ejh.12677; epub ahead of print].
  • 15. Sayago I. Impact of proteosomal inhibitors on cardiac AL amyloid. Heart Failure Association 2015 Summer Congress.
  • 16. D’Souza A, Dispenzieri A, Wirk B et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J Clin Oncol 2015; 33(32): 3741-3749.
  • 17. Cornell RF, Zhong X, Arce-Lara C et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant 2015; 50(7): 914-917.
  • 18. Wechalekar AD, Schonland SO, Kastritis E et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121(17): 3420-3427.
  • 19. Wall JS, Kennel SJ, Williams A et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012; 7(12): e52686.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.